StreetInsider.com News Articles

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Fri, 28 Nov 2025 00:00:00 +0000

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html

SITO Mobile Adds Lowell W. Robinson to Board of Directors

Wed, 19 Apr 2017 16:05:00 +0000

si-local-file:///var/storage/newsbody/2017/0419/12792822.html